Australian Rheumatology Association Database  

What is ARAD?

  • It is a national Australian database which collects important health information from individuals with inflammatory arthritis such as:

Rheumatoid arthritis
Ankylosing spondylitis
Juvenile arthritis
Psoriatic arthritis

  • The aim of ARAD is to determine effectiveness and safety of new biological drugs used to treat inflammatory arthritis condition, such as Enbrel, Remicade, Humira, Kineret, MabThera and Orencia.
  • ARAD collects information from patients every 6 months via questionnaires. Questions about medical history, medication history, responses to medication, physical functioning and quality of life are included.
  • Patients and rheumatologists across Australia contribute to ARAD.
  • Access ARAD Governance document here.
Further details in the Participant Brochure

The benefits of participating in and supporting ARAD

  • ARAD provides a valuable resource for all patients with this chronic disease and their clinicians by monitoring individual patient outcomes and adverse events.
  • Annual reports are provided to participating rheumatologists with the progress of their own patients as well as comparing their patients to the ARAD population.
  • Information on the ARAD population is provided to participants, clinicians, researchers and policy makers. This is combined information only and contains nothing that would allow an individual to be identified.
  • Regular newsletters are provided to participants updating them with information about ARAD. Click here for all newsletters.

ARAD is funded by:

Unrestricted Educational Grants administered through the ARA from:
AbbVie Pty Ltd
Pfizer Australia
Bristol-Myers Squibb Australia Pty Ltd

Previous Sponsors

Amgen Australia Pty Ltd, Aventis, Roche, NHMRC Enabling Grant, Monash University, Cabrini Health

Click for easy access: